➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Dow
McKinsey
Express Scripts
Baxter

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Patent: 8,952,043

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,952,043
Title:Benzoxepin PI3K inhibitor compounds and methods of use
Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z.sup.1 is CR.sup.1 or N; Z.sup.2 is CR.sup.2 or N; Z.sup.3 is CR.sup.3 or N; Z.sup.4 is CR.sup.4 or N; and where (i) X.sup.1 is N and X.sup.2 is S, (ii) X.sup.1 is S and X.sup.2 is N, (iii) X.sup.1 is CR.sup.7 and X.sup.2 is S, (iv) X.sup.1 is S and X.sup.2 is CR.sup.7; (v) X.sup.1 is NR.sup.8 and X.sup.2 is N, (vi) X.sup.1 is N and X.sup.2 is NR.sup.8, (vii) X.sup.1 is CR.sup.7 and X.sup.2 is O, (viii) X.sup.1 is O and X.sup.2 is CR.sup.7, (ix) X.sup.1 is CR.sup.7 and X.sup.2 is C(R.sup.7).sub.2, (x) X.sup.1 is C(R.sup.7).sub.2 and X.sup.2 is CR.sup.7; (xi) X.sup.1 is N and X.sup.2 is O, or (xii) X.sup.1 is O and X.sup.2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##
Inventor(s): Blaquiere; Nicole (San Francisco, CA), Do; Steven (San Jose, CA), Dudley; Danette (Pacifica, CA), Folkes; Adrian (Berkshire, GB), Goldsmith; Richard (Belmont, CA), Heald; Robert (Harlow, GB), Heffron; Timothy (Burlingame, CA), Kolesnikov; Aleksandr (San Francisco, CA), Ndubaku; Chudi (San Francisco, CA), Olivero; Alan G. (Half Moon Bay, CA), Price; Stephen (Harlow, GB), Staben; Steven (San Francisco, CA), Wei; BinQing (Belmont, CA)
Assignee: Genetech, Inc. (South San Francisco, CA)
Application Number:14/162,520
Patent Claims:see list of patent claims

Details for Patent 8,952,043

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2039-02-26
Genentech, Inc. PERJETA pertuzumab Injection 125409 2012-06-08 ⤷  Try it Free 2039-02-26
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Try it Free 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
AstraZeneca
Medtronic
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.